Orion Corporation raises 2026 revenue and operating profit outlook

Orion Corporation has upgraded its full-year financial outlook for 2026, citing faster-than-expected growth in royalty income during the first nine months of the year.

The pharmaceutical company now expects net sales to reach between EUR 2.07 billion and EUR 2.14 billion, up from the previous guidance of EUR 2.00 billion to EUR 2.10 billion. Additionally, the operating profit forecast has been raised to a range of EUR 730 million to EUR 790 million, compared to the previous estimate of EUR 650 million to EUR 750 million.

Orion is scheduled to publish its interim report for the period of January to September 2026 on October 28, 2026.